Acceleron to Participate in Two Healthcare Investor Conferences in February

Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences in February.

Conference Details:

    
      
        
          Event:
        
        
           
        
        
           
        
        
           
        
        
          LEERINK Partners 6th Annual Global Healthcare Conference
        
      
      
        
          Date/Time:
        
        
        
        
        
        
        
        
          February 16, 2017 at 1:00 p.m. EST
        
      
      
        
          Location:
        
        
        
        
        
        
        
        
          New York, NY
        
      
      
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Event:
        
        
        
        
        
        
        
        
          Jefferies’ Celgene Collaborators Summit
        
      
      
        
          Date/Time:
        
        
        
        
        
        
        
        
          February 21, 2017
        
      
      
        
          Location:
        
        
        
        
        
        
        
        
          New York, NY
        
      
      
        
        
        
        
        
        
        
        
        
           
        
      
    
    

A live audio webcast for the LEERINK Partners Global Healthcare Conference will be available on the Investors page of the Company's website at www.acceleronpharma.com. A replay of the webcast will be available approximately two hours after the event on the Acceleron website.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the body’s ability to rebuild and repair its own cells and tissues. This approach to drug discovery has generated four therapeutic candidates that are currently in clinical trials. The Company’s lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases, myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170201005134/en/

Acceleron Pharma Inc.Todd James, IRC, 617-649-9393Senior Director, Investor Relations and Corporate CommunicationsorMedia:BMC CommunicationsBrad Miles, 646-513-3125